Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Effect of adipose tissue-derived mesenchymal stem cells versus melatonin on skeletal muscle of reserpine-induced fibromyalgia in adult male albino rat model: Histological, behavioral, and biochemical studies.

El-Beltagi EM., Abumandour M., El-Harty YM., Shukry M., Abo-Elyazed AAE.

Animal Study on Chronic Inflammation, published in Tissue Cell (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Tissue Cell (2026)
Country
Scotland
Reported sample size
—
Source database
PubMed
PMID
42468470
DOI
10.1016/j.tice.2026.103762

Abstract (original English)

Fibromyalgia (FM) is a chronic disorder marked by ongoing musculoskeletal pain and weakness, with only symptomatic treatments available. Reserpine, a natural alkaloid, can cause symptoms resembling FM. Melatonin is a hormone with anti-inflammatory and antioxidant properties. Adipose tissue-derived mesenchymal stem cells (AD-MSCs) represent a novel approach for treating various diseases. This experimental study aimed to assess and compare the therapeutic capacity of melatonin and AD-MSCs in alleviating reserpine-induced FM changes in rats. Eighty adult male albino rats were categorized equally into four groups: control group I; group II, which was subcutaneously injected with reserpine (1 mg/kg) once daily over the flank for three continuous days to induce FM; group III, which was induced for FM as in group II, then orally received melatonin (5 mg/kg) once daily for four weeks; and group IV, which was induced for FM as in group II, then IV injected once by AD-MSCs (1 ×10 6 /rat). Behavioral tests were performed to assess motor, pain, and depressive-related behaviours. Blood and gastrocnemius muscle specimens were collected for biochemical, histological, morphometric, ultrastructural, and statistical studies. Group II exhibited marked deterioration in the behavioral and biochemical profile and enormous structural changes, including splitting of muscle fibers and sarcoplasmic loss

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research